Trial Profile
A Retrospective Study Assessing the Efficacy of Gefitinib According to Body Mass Index, Body Surface Area and Body Weight in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jul 2017
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Jul 2017 New trial record